Published in Clin Vaccine Immunol on May 18, 2011
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
Seroepidemiology of norovirus-associated travelers' diarrhea. J Travel Med (2014) 1.43
Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol (2011) 1.10
Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol (2015) 1.01
Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol (2012) 0.97
Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis (2015) 0.96
Ultra-sensitive immunoassay biosensors using hybrid plasmonic-biosilica nanostructured materials. J Biophotonics (2014) 0.81
A time-resolved immunoassay to measure serum antibodies to the rotavirus VP6 capsid protein. J Virol Methods (2012) 0.76
Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response. J Virol (2016) 0.76
Flow-through microfluidic immunosensors with refractive index-matched silica monoliths as volumetric optical detection elements. Sens Actuators B Chem (2017) 0.75
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med (1977) 4.80
Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis (1994) 4.37
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995. J Med Virol (1997) 2.70
Comparison of the reactivities of baculovirus-expressed recombinant Norwalk virus capsid antigen with those of the native Norwalk virus antigen in serologic assays and some epidemiologic observations. J Clin Microbiol (1993) 2.58
The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 2.49
The 3' end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein. J Virol (2003) 2.38
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Antigenic mapping of the recombinant Norwalk virus capsid protein using monoclonal antibodies. Virology (1996) 2.01
Subclass-specific serum antibody responses to recombinant Norwalk virus capsid antigen (rNV) in adults infected with Norwalk, Snow Mountain, or Hawaii virus. J Clin Microbiol (1993) 1.63
Detection of immunoglobulin M (IgM), IgA, and IgG Norwalk virus-specific antibodies by indirect enzyme-linked immunosorbent assay with baculovirus-expressed Norwalk virus capsid antigen in adult volunteers challenged with Norwalk virus. J Clin Microbiol (1994) 1.33
Detection of hepatitis B surface antigen using time-resolved fluoroimmunoassay. Nature (1983) 1.07
Detection of Norwalk virus and other genogroup 1 human caliciviruses by a monoclonal antibody, recombinant-antigen-based immunoglobulin M capture enzyme immunoassay. J Clin Microbiol (1998) 0.98
Simultaneous quadruple-label fluorometric immunoassay of thyroid-stimulating hormone, 17 alpha-hydroxyprogesterone, immunoreactive trypsin, and creatine kinase MM isoenzyme in dried blood spots. Clin Chem (1992) 0.97
Synthesis, characterization, and application of Eu(III), Tb(III), Sm(III), and Dy(III) lanthanide chelate nanoparticle labels. Anal Chem (2005) 0.95
A multiparameter screening assay to assess the cytokine-induced expression of endothelial cell adhesion molecules. Anal Biochem (2002) 0.84
Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut (2012) 12.62
Traces of human migrations in Helicobacter pylori populations. Science (2003) 11.92
Norovirus gastroenteritis. N Engl J Med (2009) 7.66
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Laboratory efforts to cultivate noroviruses. J Gen Virol (2004) 4.41
Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol (2011) 3.87
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med (2011) 3.78
Norwalk virus shedding after experimental human infection. Emerg Infect Dis (2008) 3.70
Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol (2005) 3.34
Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology (2002) 3.27
Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol (2003) 3.15
The peopling of the Pacific from a bacterial perspective. Science (2009) 3.14
Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol (2012) 2.99
Gastroesophageal reflux among different racial groups in the United States. Gastroenterology (2004) 2.87
Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol (2004) 2.83
Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Arch Virol (2008) 2.77
Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) (2002) 2.75
Age at acquisition of Helicobacter pylori infection: a follow-up study from infancy to adulthood. Lancet (2002) 2.71
Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 2.59
Helicobacter pylori in North and South America before Columbus. FEBS Lett (2002) 2.57
Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol (2005) 2.54
Atomic resolution structural characterization of recognition of histo-blood group antigens by Norwalk virus. Proc Natl Acad Sci U S A (2008) 2.54
Rotavirus antigenaemia and viraemia: a common event? Lancet (2003) 2.51
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
The epidemiologic and clinical importance of norovirus infection. Gastroenterol Clin North Am (2006) 2.49
Noroviruses everywhere: has something changed? Curr Opin Infect Dis (2006) 2.44
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis (2006) 2.43
The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.43
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
The 3' end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein. J Virol (2003) 2.38
Structural requirements for the assembly of Norwalk virus-like particles. J Virol (2002) 2.38
Norwalk virus infection associates with secretor status genotyped from sera. J Med Virol (2005) 2.34
Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology (2002) 2.32
Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis (2010) 2.21
Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol (2009) 2.15
X-ray structure of a native calicivirus: structural insights into antigenic diversity and host specificity. Proc Natl Acad Sci U S A (2006) 2.09
Rotaviruses: from pathogenesis to vaccination. Gastroenterology (2009) 2.05
Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med (2011) 2.04
Comparing the Blatchford and pre-endoscopic Rockall score in predicting the need for endoscopic therapy in patients with upper GI hemorrhage. Gastrointest Endosc (2010) 2.04
Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology (2005) 2.03
Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter (2009) 2.02
Optimal therapy for Helicobacter pylori infections. Nat Rev Gastroenterol Hepatol (2011) 1.98
Magnet ingestions in children presenting to US emergency departments, 2002-2011. J Pediatr Gastroenterol Nutr (2013) 1.98
Gastritis staging in clinical practice: the OLGA staging system. Gut (2006) 1.90
Complications of pediatric EGD: a 4-year experience in PEDS-CORI. Gastrointest Endosc (2007) 1.89
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol (2003) 1.89
Respiratory viral infections in patients with chronic, obstructive pulmonary disease. J Infect (2005) 1.83
Neonatal infection with G10P[11] rotavirus did not confer protection against subsequent rotavirus infection in a community cohort in Vellore, South India. J Infect Dis (2007) 1.83
Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine (2003) 1.83
Inter- and intragenus structural variations in caliciviruses and their functional implications. J Virol (2004) 1.79
Risk factors for immediate and delayed bleeding associated with endoscopic submucosal dissection of gastric neoplastic lesions. Scand J Gastroenterol (2009) 1.75
NSAIDs, Helicobacter pylori, and Pandora's Box. N Engl J Med (2002) 1.75
Noroviruses: The leading cause of gastroenteritis worldwide. Discov Med (2010) 1.73
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter (2011) 1.73
Discrimination between cases of duodenal ulcer and gastritis on the basis of putative virulence factors of Helicobacter pylori. J Clin Microbiol (2002) 1.72
Evolutionary trace residues in noroviruses: importance in receptor binding, antigenicity, virion assembly, and strain diversity. J Virol (2005) 1.71
Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol (2010) 1.69
Patterns of gastric atrophy in intestinal type gastric carcinoma. Cancer (2002) 1.69
Biliary stenting in the management of large or multiple common bile duct stones. Gastrointest Endosc (2010) 1.68
Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med (2006) 1.68
Norwalk virus RNA is infectious in mammalian cells. J Virol (2007) 1.66
Cell attachment protein VP8* of a human rotavirus specifically interacts with A-type histo-blood group antigen. Nature (2012) 1.65
Norwalk virus-specific binding to oyster digestive tissues. Emerg Infect Dis (2006) 1.63
Management of gastric polyps: a pathology-based guide for gastroenterologists. Nat Rev Gastroenterol Hepatol (2009) 1.62
The prevalence of suspected Barrett's esophagus in children and adolescents: a multicenter endoscopic study. Gastrointest Endosc (2006) 1.60
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Helicobacter pylori infection in mice: Role of outer membrane proteins in colonization and inflammation. Gastroenterology (2002) 1.58
Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol (2005) 1.57
Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res (2002) 1.56
Replication and packaging of Norwalk virus RNA in cultured mammalian cells. Proc Natl Acad Sci U S A (2005) 1.56
Endoscopic demonstration of transient small bowel intussusception in a patient with adult celiac disease. Gastrointest Endosc (2003) 1.55
Identification of Genogroup I and Genogroup II broadly reactive epitopes on the norovirus capsid. J Virol (2005) 1.53
Structural analysis of histo-blood group antigen binding specificity in a norovirus GII.4 epidemic variant: implications for epochal evolution. J Virol (2011) 1.53
Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol (2006) 1.51
Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol (2012) 1.51